Despite the quest for new treatments to stop, slow or prevent AD, researchers around the world are looking for new sources of AChE inhibitors also, because of the concerns around the bioavailability and side-effects issues, associated with the existing, mostly synthetic, drugs for AD. Here, ACHE is linked to Alzheimer disease.